ddp4 and glp 1 together Mechanisms of dipeptidyl peptidase‐4 (DPP‐4) inhibitors, glucagon‐like Mechanism of action for GIP,
Description
www.heart.org
[DOI] [PMC free article] [PubMed] [Google Scholar] 15.Mann JF, Anderson C, Gao P, Gerstein HC, Boehm M, Ryden L, et al
Summary of completed and ongoing clinical trials of GLP-1RAs for neurodegeneration In summary, clinical trials investigating GLP-1RAs in neurodegenerative diseases have yielded contrasting outcomes
A recent meta-analysis indicates that GLP-1 RAs significantly reduce major adverse cardiovascular events by 14%, cardiovascular death by 14%, hospitalization for heart failure by 13% [6]
GLP-1's ability to suppress food reward behavior is a new concept
Cardiovascular outcomes GLP-1 receptor agonists have demonstrated cardiovascular risk reduction in large outcome trials
